News Virax Biolabs Group Limited

Equities

VRAX

KYG9495L1251

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 21/01/2026 GMT			5-day change	1st Jan Change
0.2730 ^USD	-4.55%		-18.07%	-21.05%

12-02	Virax Biolabs Group Limited announced that it expects to receive $5 million in funding	CI
12-02	Virax Biolabs Group Limited Reports Earnings Results for the Half Year Ended September 30, 2025	CI

12-04	Virax Biolabs : Announces Closing of $5 Million Private Placement	PU
12-04	Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement	PR
12-03	Virax Biolabs : Announces $5 Million Private Placement	PU
12-03	Virax Biolabs Group Limited Announces $5 Million Private Placement	PR
12-03	Virax Biolabs' : CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders	PU
12-03	Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders	PR
12-02	Virax Biolabs Group Limited announced that it expects to receive $5 million in funding	CI
12-02	Virax Biolabs Group Limited Reports Earnings Results for the Half Year Ended September 30, 2025	CI
11-03	Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes	PR
11-03	Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive Fda Feedback for Viraximmune?? Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes	CI
27/10/25	Virax Biolabs : Investor Presentation (Virax Biolabs Investor Deck October 2025 FINAL V2)	PU
10/10/25	Virax Biolabs : Investor Presentation (Virax Biolabs Investor Deck October 2025)	PU
26/08/25	Virax Biolabs to Collaborate With Emory University on Long COVID Clinical Studies	MT
26/08/25	Virax Biolabs : Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early SeptemberV	PU
26/08/25	Virax Biolabs partners with Emory University on ViraxImmune(TM) clinical studies	RE
26/08/25	Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September	PR
26/08/25	Virax Biolabs Group Limited Partners with Emory University on ViraxImmune Clinical Studies	CI
08/08/25	Virax Biolabs : Major New Study Reveals Immunological Insights Into ME/CFS, Further Supporting Blood-based Diagnostic Testing and Research	PU
29/07/25	Virax Biolabs Group Limited Announces Board Changes	CI
29/07/25	Virax Biolabs Group appoints Iain Miller, Ph.D. as independent director to accelerate commercial strategy	RE
29/07/25	Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy	PR
18/07/25	Virax Biolabs Gets Nasdaq Non-Compliance Notice	MT
18/07/25	Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency	PR
09/07/25	Virax Biolabs : Investor Presentation (Virax Biolabs Investor Deck July 2025)	PU
02/07/25	Virax Biolabs Group Limited Reports Earnings Results for the Full Year Ended March 31, 2025	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

News Virax Biolabs Group Limited

Equities

VRAX

KYG9495L1251

Biotechnology & Medical Research

Filters